Parkinson's disease gene therapy - Avigen

Drug Profile

Parkinson's disease gene therapy - Avigen

Latest Information Update: 27 Jun 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avigen
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 27 Jun 2003 Discontinued - Preclinical for Parkinson's disease in USA (Injection)
  • 16 Aug 2002 This gene therapy is still in active development
  • 28 Jul 1998 An animal study was added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top